Locations:
Search
Combination therapy doubles the number of meaningful spleen volume responses over monotherapy
Making sense of the fast-moving treatment landscape
Combination therapy may help address underlying disease
Highlighting treatment gaps and challenges in the management of rare condition
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Explaining common misconceptions about chimeric antigen receptor therapy
Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma
Optimized responses in transplant- and CAR T-cell therapy-eligible patients
Findings from large database important to inform clinical practice
Offers a new option for patients 60 and older with relapsed/refractory disease
What’s coming up at ASH and beyond
Advertisement
Advertisement